Screener Summaries Updates Institutions Sign In More Updates › Other Events › CLYM Other Events · Jun 8, 2026
At the 2026 Annual Meeting of Stockholders, Climb Bio, Inc. stockholders approved an amendment to the 2021 Equity… CLYM Climb Bio, Inc.
At the 2026 Annual Meeting of Stockholders, Climb Bio, Inc. stockholders approved an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the calculation of the annual share pool increase. Additionally, Alexander (Bo) Cumbo and Douglas Williams, Ph.D., were elected to the Board of Directors, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm.
More from Climb Bio, Inc. Climb Bio reports Q3 net loss of $14.6 million; holds $227.6 million in cash Nov 5, 2026 Climb Bio reports initial Phase 2 PrisMN data for budoprutug in pMN showing 70% PLA2R reduction Oct 26, 2026 Climb Bio reports CLYM116 Phase 1 data showing ~70% Gd-IgA1 reduction at 12 weeks Oct 23, 2026 On September 3, 2026, Climb Bio announced positive initial data from its Phase 1 trial of CLYM116, an anti-APRIL… Sep 3, 2026 Climb Bio reported second quarter 2026 financial results on August 6, 2026, showing a net loss of $13.5 million… Aug 6, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
